Company news

CNS Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

August 26, 2024

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

August 21, 2024

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 14, 2024

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

July 29, 2024

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

July 24, 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

July 15, 2024

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

July 2, 2024

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

June 25, 2024

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 19, 2024

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

May 15, 2024

CNS Pharmaceuticals to Present at the LSX World Congress 2024

April 22, 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

April 21, 2024

CNS Pharmaceuticals to Present at Two Investor Conferences in April

March 31, 2024

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

March 31, 2024

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

January 28, 2024

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

January 17, 2024

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

January 16, 2024

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

December 17, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

November 21, 2023

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

November 15, 2023

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

November 14, 2023

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

October 18, 2023

CNS Pharmaceuticals' (NASDAQ: CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date

October 10, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)

September 6, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

August 13, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

August 13, 2023

CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference

August 2, 2023

CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

August 2, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference

July 26, 2023

CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series

July 4, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

June 13, 2023

CNS Pharmaceuticals (NASDAQ: CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

May 24, 2023

CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 14, 2023

Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors

May 7, 2023

CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC

May 2, 2023

CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study

April 26, 2023

Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 9, 2023

CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

April 5, 2023

CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

April 2, 2023

CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event

March 28, 2023

CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues

March 12, 2023

CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland

March 8, 2023

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

February 6, 2023

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland

January 11, 2023

CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

January 4, 2023

CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors

January 2, 2023

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

December 7, 2022

CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event

December 4, 2022

CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price

November 29, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 24 decks. Every deck is listed under its year.